ArticlePloS one2025
A novel preparation method for monodisperse streptavidin magnetic beads and its application in electrochemiluminescent immunoassay for CEA.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Oxidation-ShieldedBiosensors · 2026Article
- An Enhanced Electrochemiluminescence Immunoassay Platform via Optimized Magnetic Bead Uniformity for Reliable Thyroid-Stimulating Hormone Monitoring.Bioengineering (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The magnetic microspheres coated with streptavidin (PS-SA) were successfully prepared by loading streptavidin onto modified hyperbranched poly(glycerol) (HPG) magnetic microspheres. This material was comprehensively characterized using various methods, including scanning electron microscopy, thermogravimetric analysis, fourier-transform infrared spectroscopy, vibrating sample magnetometry and zeta potential measurement. This study introduced a novel electrochemiluminescence immunoassay utilizing functionalized magnetic microspheres for the ultrasensitive detection of carcinoembryonic antigen (CEA). The sensor employed Ru(bpy)32+-labeled anti-CEA-Ab2 (Ru-Ab2) as the signal probe and combined it with monodisperse streptavidin magnetic beads and biotinylated anti-CEA-Ab1 (bio-Ab1) to selectively capture CEA. Under optimized conditions, the immunosensor exhibited a broad linear range from 0.05 to 1000 ng/mL for CEA detection (R² = 0.998), along with an exceptionally low detection limit (LOD) of 0.02383 ng/mL. Moreover, the developed immunosensor demonstrated remarkable selectivity, excellent stability, and satisfactory reproducibility, indicating its significant potential for clinical diagnostic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.